



**LTT regarding the use of the Johnson & Johnson COVID-19 vaccine in Denmark**

---

- The Danish Medicines Agency and the Danish Health Authority agree with EMA that the Johnson & Johnson vaccine is effective and support EMA's general assessment that the benefits of the vaccine outweigh the risks.
- Given the current epidemiological situation in Denmark, where the majority of persons at risk have been vaccinated, or are scheduled to be vaccinated, and where the level of epidemic control continues to be at a stable point, the Danish Health Authority has decided to continue the national vaccine roll-out without the vaccine from Johnson & Johnson.
- The Danish Health Authority has weighed the current epidemiological situation in Denmark against the specific risk profile of the vaccine.
- It is a decision taken regarding a concrete vaccine in a concrete epidemiological situation. Had the situation in Denmark been different, the decision not to utilize the specific vaccine could have been different.

The Johnson & Johnson vaccine will still be approved for use in Denmark and the contract with Johnson & Johnson will continue. The Danish Health Authority has not ruled out that the vaccine could be resumed in the Danish national vaccination programme if the situation changes. If an optional roll-out of the AstraZeneca vaccine is established in Denmark, as a supplement to the national vaccine program, the Johnson & Johnson vaccine could possibly be included in this.

- The Danish Health Authority finds that Denmark has a global responsibility to support research to generate knowledge regarding the COVID-19 vaccines and will therefore continue to support the use of the Johnson & Johnson vaccine in protocolled research studies in Denmark.
- The Danish Government has not yet decided on how to utilize possible excess vaccines from Johnson & Johnson and AstraZeneca.